Editorial: The use of Baveno VI and VII criteria in patients with hepatocellular carcinoma

Affiliations

Editorial

Carlos Moctezuma-Velazquez et al. Aliment Pharmacol Ther. 2023 Aug.

. 2023 Aug;58(4):478-479.

doi: 10.1111/apt.17626.

¹ Division of Gastroenterology (Liver Unit), Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

No abstract available

Comment in

Editorial: The use of Baveno VI and VII criteria for portal hypertension and varices in patients with hepatocellular carcinoma-Authors' reply.
Allaire M, Thabut D. Allaire M, et al. Aliment Pharmacol Ther. 2023 Aug;58(4):480-481. doi: 10.1111/apt.17648. Aliment Pharmacol Ther. 2023. PMID: 37499107 No abstract available.

Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma.
Allaire M, Campion B, Demory A, Larrey E, Wagner M, Rudler M, Roux C, Blaise L, Carrie NG, Thabut D. Allaire M, et al. Aliment Pharmacol Ther. 2023 Aug;58(3):346-356. doi: 10.1111/apt.17599. Epub 2023 Jun 9. Aliment Pharmacol Ther. 2023. PMID: 37300315

1. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Faculty BV. Baveno VII-renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-74. https://doi.org/10.1016/j.jhep.2021.12.022
1. de Franchis R, Faculty BV. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743-52. https://doi.org/10.1016/j.jhep.2015.05.022
1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681-93. https://doi.org/10.1016/j.jhep.2021.11.018
1. Allaire M, Campion B, Demory A, Larrey E, Wagner M, Rudler M, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:346-56. https://doi.org/10.1111/apt.17599
1. Souhami A, Sartoris R, Rautou PE, Cauchy F, Bouattour M, Durand F, et al. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. JHEP Rep. 2020;2(5):100147. https://doi.org/10.1016/j.jhepr.2020.100147